CA2959158A1 - Medical treatments based on anamorelin - Google Patents

Medical treatments based on anamorelin Download PDF

Info

Publication number
CA2959158A1
CA2959158A1 CA2959158A CA2959158A CA2959158A1 CA 2959158 A1 CA2959158 A1 CA 2959158A1 CA 2959158 A CA2959158 A CA 2959158A CA 2959158 A CA2959158 A CA 2959158A CA 2959158 A1 CA2959158 A1 CA 2959158A1
Authority
CA
Canada
Prior art keywords
anamorelin
patient
therapeutically effective
cachexia
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2959158A
Other languages
English (en)
French (fr)
Inventor
William Mann
John Friend
William Polvino
Suzan ALLEN
Ming Lu
Elizabeth DUUS
Enrico Baroni
Ruben Giorgino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinn Healthcare SA
Original Assignee
Helsinn Healthcare SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2959158(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare SA filed Critical Helsinn Healthcare SA
Publication of CA2959158A1 publication Critical patent/CA2959158A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2959158A 2014-09-04 2015-08-28 Medical treatments based on anamorelin Pending CA2959158A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
US62/045,976 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Publications (1)

Publication Number Publication Date
CA2959158A1 true CA2959158A1 (en) 2016-03-10

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2959158A Pending CA2959158A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Country Status (44)

Country Link
US (5) US9675600B2 (https=)
EP (2) EP3590338A3 (https=)
JP (3) JP6356907B2 (https=)
KR (3) KR102307275B1 (https=)
CN (5) CN113577073A (https=)
AP (1) AP2017009772A0 (https=)
AR (1) AR103118A1 (https=)
AU (1) AU2015312231B2 (https=)
BR (1) BR112017003552A2 (https=)
CA (1) CA2959158A1 (https=)
CL (1) CL2017000494A1 (https=)
CO (1) CO2017003263A2 (https=)
CR (1) CR20170121A (https=)
CY (1) CY1122746T1 (https=)
DK (1) DK3188599T3 (https=)
DO (1) DOP2017000055A (https=)
EA (1) EA035578B1 (https=)
EC (1) ECSP17019893A (https=)
ES (1) ES2761777T3 (https=)
GE (2) GEAP201814459A (https=)
HR (1) HRP20192345T1 (https=)
HU (1) HUE046894T2 (https=)
IL (1) IL250692B (https=)
JO (1) JO3541B1 (https=)
LT (1) LT3188599T (https=)
MA (1) MA40607B1 (https=)
MD (1) MD4710C1 (https=)
ME (1) ME03597B (https=)
MX (1) MX361741B (https=)
MY (1) MY187167A (https=)
NI (1) NI201700024A (https=)
PE (1) PE20171109A1 (https=)
PH (1) PH12017500392B1 (https=)
PL (1) PL3188599T3 (https=)
PT (1) PT3188599T (https=)
RS (1) RS59751B1 (https=)
SG (1) SG11201701567UA (https=)
SI (1) SI3188599T1 (https=)
SV (1) SV2017005400A (https=)
TN (1) TN2017000040A1 (https=)
TW (1) TWI639429B (https=)
UA (1) UA120765C2 (https=)
UY (1) UY36286A (https=)
WO (1) WO2016036598A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
GEAP201814459A (en) 2014-09-04 2018-09-10 Helsinn Healthcare Sa Medical treatments based on anamorelin
US12433945B2 (en) 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
US12226448B2 (en) 2018-12-20 2025-02-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy dosing schedule for missed doses
CA3137295A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
CN115569120A (zh) 2019-08-30 2023-01-06 赫尔森保健股份公司 具有改善稳定性的阿拉莫林片剂的生产方法
KR20220087427A (ko) 2019-10-24 2022-06-24 도레이 카부시키가이샤 악액질의 치료제 또는 예방제
JP2024534464A (ja) * 2021-09-17 2024-09-20 小野薬品工業株式会社 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法
WO2025004650A1 (ja) * 2023-06-28 2025-01-02 日清オイリオグループ株式会社 中高年者の疲労感を軽減するための剤及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
EP1660117A2 (en) 2003-08-06 2006-05-31 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
KR20070010151A (ko) 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
US7825138B2 (en) * 2004-06-29 2010-11-02 Helsinn Therapeutics (U.S.), Inc. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
CA2677813A1 (en) * 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
KR20150020602A (ko) * 2012-05-25 2015-02-26 라퀄리아 파마 인코포레이티드 무산증 치료를 위한 그렐린 수용체 효능물질
GEAP201814459A (en) 2014-09-04 2018-09-10 Helsinn Healthcare Sa Medical treatments based on anamorelin

Also Published As

Publication number Publication date
ME03597B (me) 2020-07-20
AU2015312231B2 (en) 2017-10-19
US20210093627A1 (en) 2021-04-01
US20160067236A1 (en) 2016-03-10
CN107205389A (zh) 2017-09-26
DOP2017000055A (es) 2017-08-15
SV2017005400A (es) 2017-04-20
EP3188599A4 (en) 2017-10-11
CN113577073A (zh) 2021-11-02
UA120765C2 (uk) 2020-02-10
MD4710C1 (ro) 2021-04-30
TN2017000040A1 (en) 2018-07-04
JP2018154655A (ja) 2018-10-04
JP2017526695A (ja) 2017-09-14
SG11201701567UA (en) 2017-03-30
JP2021080281A (ja) 2021-05-27
JP6356907B2 (ja) 2018-07-11
MY187167A (en) 2021-09-07
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
TWI639429B (zh) 2018-11-01
MX361741B (es) 2018-12-14
PE20171109A1 (es) 2017-08-07
AR103118A1 (es) 2017-04-19
CO2017003263A2 (es) 2017-07-28
MA40607B1 (fr) 2019-11-29
MD20170025A2 (ro) 2017-07-31
NZ729673A (en) 2023-09-29
PL3188599T3 (pl) 2020-06-01
UY36286A (es) 2016-02-29
EP3188599A1 (en) 2017-07-12
KR20210035923A (ko) 2021-04-01
EP3590338A2 (en) 2020-01-08
BR112017003552A2 (pt) 2017-12-05
PH12017500392A1 (en) 2017-07-17
LT3188599T (lt) 2019-12-10
NI201700024A (es) 2017-07-18
KR102234319B1 (ko) 2021-04-01
CN107375285A (zh) 2017-11-24
MX2017002825A (es) 2017-09-28
AP2017009772A0 (en) 2017-02-28
CR20170121A (es) 2017-07-17
ES2761777T3 (es) 2020-05-21
GEAP201814459A (en) 2018-09-10
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
US20240024303A1 (en) 2024-01-25
CN109172575A (zh) 2019-01-11
RS59751B1 (sr) 2020-02-28
KR20180085047A (ko) 2018-07-25
ECSP17019893A (es) 2017-05-31
KR102307275B1 (ko) 2021-09-30
US10278964B2 (en) 2019-05-07
EP3590338A3 (en) 2020-03-18
KR101881264B1 (ko) 2018-07-23
IL250692B (en) 2019-05-30
JP7044918B2 (ja) 2022-03-30
US9675600B2 (en) 2017-06-13
PT3188599T (pt) 2020-01-15
JO3541B1 (ar) 2020-07-05
PH12017500392B1 (en) 2018-08-31
US10894041B2 (en) 2021-01-19
EP3188599B1 (en) 2019-10-02
JP6923486B2 (ja) 2021-08-18
WO2016036598A1 (en) 2016-03-10
CL2017000494A1 (es) 2017-09-15
US11723902B2 (en) 2023-08-15
CY1122746T1 (el) 2021-03-12
CN113577074A (zh) 2021-11-02
HRP20192345T1 (hr) 2020-03-20
IL250692A0 (en) 2017-04-30
MD4710B1 (ro) 2020-09-30
KR20170047372A (ko) 2017-05-04
US20170296526A1 (en) 2017-10-19
HUE046894T2 (hu) 2020-04-28
TW201613587A (en) 2016-04-16
AU2015312231A1 (en) 2017-03-23
US20190175574A1 (en) 2019-06-13
SI3188599T1 (sl) 2020-02-28

Similar Documents

Publication Publication Date Title
US20240024303A1 (en) Medical Treatments Based on Anamorelin
Richards et al. Comparison of the efficacy and safety of dual-opioid treatment with morphine plus oxycodone versus oxycodone/acetaminophen for moderate to severe acute pain after total knee arthroplasty
HK40020876A (en) Medical treatments based on anamorelin
HK1234959B (en) Medical treatments based on anamorelin
HK1234959A1 (en) Medical treatments based on anamorelin
OA18229A (en) Medical treatments based on anamorelin.
NZ729673B2 (en) Medical treatments based on anamorelin
KR102481026B1 (ko) 인터루킨 23의 항체를 포함하는 화학요법유발 말초신경병증의 예방 또는 치료용 약학적 조성물
JP2020525548A (ja) 炎症反応を伴う疼痛状態における鎮痛のための末梢限局的二重作用性κおよびδオピオイドアゴニスト
US20170252311A1 (en) Sphingosine kinase inhibitors and ceramide for maintenance therapy of glioblastoma
AU2007358742A1 (en) Methods and compositions for treating melanoma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200713

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250724

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250918

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251127